Temp excursion of 17.2°F-43.3°F on 29Dic2022; This case was reported by a other health professional via call center representative and described the occurrence of incorrect storage of drug in a patient who received Men B NVS (Bexsero) for prophylaxis.   Co-suspect products included meningococcal B recom vaccine + aloh + omv pre-filled syringe device (Bexsero Pre-Filled Syringe Device) injection syringe for prophylaxis, DTPa (Reduced antigen) (Boostrix) for prophylaxis, HBV (Engerix B) for prophylaxis, DTPa (Infanrix) for prophylaxis, dtpa vaccine pre-filled syringe device (Infanrix Pre-Filled Syringe Device) injection syringe for prophylaxis, DTPa-IPV (Kinrix) for prophylaxis, dtpa-ipv vaccine pre-filled syringe device (Kinrix Pre-Filled Syringe Device) injection syringe for prophylaxis, DTPa-HBV-IPV (Pediarix) for prophylaxis, dtpa-hbv-ipv vaccine pre-filled syringe device (Pediarix Pre-Filled Syringe Device) injection syringe for prophylaxis, Rota (Rotarix lyophilized formulation) for prophylaxis, rotavirus vaccine oral applicator device (Rotarix Oral Applicator Device) oral applicator for prophylaxis, Flu Seasonal QIV Dresden (Fluarix Tetra) for prophylaxis and flu seasonal qiv dresden pre-filled syringe device (Fluarix Tetra Pre-Filled Syringe Device) injection syringe for prophylaxis.   On an unknown date, the patient received Bexsero, Bexsero Pre-Filled Syringe Device, Boostrix, Engerix B, Infanrix, Infanrix Pre-Filled Syringe Device, Kinrix, Kinrix Pre-Filled Syringe Device, Pediarix, Pediarix Pre-Filled Syringe Device, Rotarix lyophilized formulation, Rotarix Oral Applicator Device, Fluarix Tetra and Fluarix Tetra Pre-Filled Syringe Device. On an unknown date, unknown after receiving Bexsero, Bexsero Pre-Filled Syringe Device, Boostrix, Engerix B, Infanrix, Infanrix Pre-Filled Syringe Device, Kinrix, Kinrix Pre-Filled Syringe Device, Pediarix, Pediarix Pre-Filled Syringe Device, Rotarix lyophilized formulation, Rotarix Oral Applicator Device, Fluarix Tetra and Fluarix Tetra Pre-Filled Syringe Device, the patient experienced incorrect storage of drug. On an unknown date, the outcome of the incorrect storage of drug was unknown.     This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 26-JAN-2023 Reporter's Comments: The reporter mentioned about a temperature excursion.  Since 29th December 2022 until the reporting day on 13th January 2023, vaccines were administered.  HCP needed time to pull up the report and see how many patients received all these vaccines after the temperature excursion. The reporter mentioned about temperature excursion of vaccines Bexsero, Boostrix, Engerix-B, Infanrix, Kinrix, Pediarix, Rotarix (no data available about presentation). Fluarix QIV vaccine was in doubt at the moment of the call. The temperature at 9.49 am was 17.2-degree F, at 9.56 am 43.3-degree F and at 10.19 am normal temperature. The reporter consented to follow up via email. Additional Supportive Information: the patients received vaccines which had undergone temperature excursion, which led to incorrect storage of drugs. It was unknown how many patients received which vaccines, and Fluarix QIV vaccine was also involved or not. Therefore, suspect and event captured conservatively.